DelveInsight’s Persistent Corneal Epithelial Defects market report offers detailed information on current treatment practices, emerging drugs, Persistent Corneal Epithelial Defects market share of the individual therapies, current and forecasted Persistent Corneal Epithelial Defects market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Spain, Germany, Italy, and France), and Japan).
Some of the Key Highlights from the Persistent Corneal Epithelial Defects Market Report
As per DelveInsight estimates, the total Persistent Corneal Epithelial Defects incidents cases was 241,452 in the 7MM in 2020.
Among the EU5 countries, Germany had the highest PCEDs incident cases in 2020.
Leading companies such as OcuNexus Therapeutics, Eyevance Pharmaceuticals, Noveome Biotherapeutics, RegeneRx Biopharmaceuticals, and others are developing novel therapies for Persistent Corneal Epithelial Defects.
Key PCEDs pipeline therapies expected to launch in the upcoming years include Nexagon, ST266, RGN-259, and others.
Nexagon (OcuNexus Therapeutics/Eyevance Pharmaceuticals) has received Orphan Drug Designation from the FDA. It is currently in the Phase II studies for PEDs
RGN-259 is a sterile and preservative-free eye drop based on Thymosin beta-4 (T4) developed as a novel treatment by RegeneRx Biopharmaceuticals.
Request for PCEDs market report sample to understand more about the emerging drug landscape @ Persistent Corneal Epithelial Defects Treatment Market Analysis
Persistent Corneal Epithelial Defects: Overview
Persistent Corneal Epithelial Defects (PEDs or PCEDs) are caused by the failure of rapid re-epithelialization and closure following a corneal injury within 10-14 days, even with standard supportive treatment. PED awareness has grown in recent years due to increased research activities across the spectrum of ophthalmology research.
Persistent Corneal Epithelial Defects Epidemiology Segmentation
The Persistent Corneal Epithelial Defects report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:
Persistent Corneal Epithelial Defects Incident Cases
Persistent Corneal Epithelial Defects Gender-Based Incident Cases
Persistent Corneal Epithelial Defects Etiology-Specific Incidence
Persistent Corneal Epithelial Defects Therapeutics Market
The current PCEDs treatment approaches include Aggressive Lubrication, Punctal Occlusion, Bandage Soft Contact Lens, Pressure Patching, Tetracyclines, Prophylactic Topical Antibiotics, and Steroids. Whereas, Amniotic Membrane Grafting, Autologous Serum, Scleral Contact Lenses, and other treatments are used to treat refractory cases.
Persistent Corneal Epithelial Defects Market Outlook
The total PCEDs market size of PCED includes the market size of both the potential upcoming therapies such as Nexagon, ST266, RGN-259, and others, along with the current treatment modalities in the 7MM.
Discover more about the future market share of the drugs @ Persistent Corneal Epithelial Defects Market Share
Persistent Corneal Epithelial Defects Pipeline Therapies and Key Companies
Nexagon: OcuNexus Therapeutics/ Eyevance Pharmaceuticals
ST266: Noveome Biotherapeutics
RGN-259: RegeneRx Biopharmaceuticals
Persistent Corneal Epithelial Defects Market Drivers
Increasing R&D activities
Emerging PCEDs Pipeline
Available Standard Therapies
Persistent Corneal Epithelial Defects Market Barriers
Lack of approved Therapies in the market
Challenges in Drug Delivery
Lack of Animal models
Scope for the Report
Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan)
Study Period: 2018-30
Persistent Corneal Epithelial Defects Key Companies: OcuNexus Therapeutics, Eyevance Pharmaceuticals, Noveome Biotherapeutics, RegeneRx Biopharmaceuticals, among others.
Persistent Corneal Epithelial Defects Key Pipeline Therapies: Nexagon, ST266, RGN-259, and others.
Persistent Corneal Epithelial Defects Segmentation: By Geography, By Persistent Corneal Epithelial Defects therapies
Analysis: Comparative and conjoint analysis of Persistent Corneal Epithelial Defects emerging therapies
Tools Used: SWOT Analysis
Case Studies
KOL’s Views
Analyst’s Views
Table of Contents
1.
Key Insights
2.
Report Introduction
3.
Persistent Corneal Epithelial Defects Market Overview at a Glance
4.
Executive Summary of Persistent Corneal Epithelial Defects
5.
Organizations contributing towards Persistent Epithelial Defect (PED)
6.
Persistent Corneal Epithelial Defects Disease Background and Overview
7.
Persistent Corneal Epithelial Defects Unmet Needs
8.
Persistent Corneal Epithelial Defects Epidemiology and Patient Population
9.
Persistent Corneal Epithelial Defects Current Treatment Practices
10.
Patient Journey
11.
Case Report
12.
Persistent Corneal Epithelial Defects Marketed Therapies
13.
Persistent Corneal Epithelial Defects Emerging Products
14.
Persistent Corneal Epithelial Defects: 7 Major Market Analysis
15.
16.
17.
18.
KOL Views
19.
SWOT Analysis
20.
Appendix
21.
Report Methodology
22.
DelveInsight Capabilities
23.
Disclaimer
24.
About DelveInsight
For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts
Related Reports
Corneal Endothelial Dystrophy Market
Get a comprehensive analysis of Corneal Endothelial Dystrophy pipeline therapies and key companies such as Aerie Pharmaceuticals, Kowa Pharmaceuticals, Trefoil Therapeutics, among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Sandeep JoshiEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: www.delveinsight.com/